AI-generated content for informational purposes only. Not financial advice. Always do your own research.

About

Clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, including a promising oral GLP-1 receptor agonist for obesity.

Weight Loss Stocks

Viking Therapeutics is developing novel oral GLP-1 therapies for metabolic disorders, offering clinical-stage pipeline exposure to the next generation of weight loss treatments.

Key Financials VKTX

Price $29.00
Change (1D) -4.89%
Change (30D) -17.57%
Change (60D) -24.12%
Change (90D) -10.16%
Change (180D) +6.89%
Change (1Y) -1.09%
Change (5Y) +219.38%
P/E Ratio 24.17
EPS (TTM) $1.20
52-Week Range $18.92 — $43.15
50-Day MA $33.25
Volume 2.94M

Data updated Feb 15 · Source: Twelve Data

3.8 1 vote

AI Reviews

🤖
3.8 /5

Viking Therapeutics is a clinical-stage biopharmaceutical company that has emerged as a compelling pure-play in the obesity/metabolic disease space, primarily through its oral GLP-1 receptor agonist VK2735. The stock has delivered impressive 5-year returns of 219%, reflecting growing investor enthusiasm for the weight loss drug market.

The bull case centers on VK2735's promising clinical data showing significant weight loss in trials, potentially offering an oral alternative to injectable competitors like Novo Nordisk and Eli Lilly. An oral formulation could be a meaningful differentiator. The surprisingly positive P/E of 24.17 and EPS of $1.20 are unusual for a clinical-stage biotech, suggesting possible one-time gains or accounting nuances worth investigating.

The bear case is notable: the stock trades 33% below its 52-week high, reflecting recent momentum deterioration with a -24% decline over 60 days. As a smaller player competing against pharmaceutical giants with massive manufacturing and commercial infrastructure, Viking faces significant execution risk. Binary clinical trial outcomes add volatility, and the path to commercialization remains long and capital-intensive.

Viking offers high-risk, high-reward exposure to the booming weight loss market, best suited for investors with strong risk tolerance.

Category Ratings

Weight Loss Stocks
3.8
Feb 15, 2026
AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more
Viking Therapeutics Screenshot

Added: Feb 15, 2026

vikingtherapeutics.com